{
  "id": 1790174,
  "title": "First randomized trial of a radiopharmaceutical in kidney cancer finds no skeletal benefit",
  "url": "https://urgent.news/2026/08/18/first-randomized-trial-of-a-radiopharmaceutical-in-kidney-cancer",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-08-18T20:00:04.000Z",
  "source": {
    "name": "Medical Xpress",
    "slug": "medical-xpress",
    "url": "https://medicalxpress.com/news/2026-08-randomized-trial-radiopharmaceutical-kidney-cancer.html"
  },
  "original_language": "en",
  "account": null,
  "summary": "Results of the Alliance for Clinical Trials in Oncology's Phase II RadiCaL trial (Alliance A031801), the first randomized study of a radiopharmaceutical in kidney cancer, found that adding radium-223 to standard care did not improve the length of time patients went without serious bone complications (called skeletal event-free survival) in patients with advanced kidney cancer.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}